BNP Paribas Financial Markets Sells 6,050 Shares of Glaukos Co. (NYSE:GKOS)

BNP Paribas Financial Markets reduced its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 44.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,676 shares of the medical instruments supplier's stock after selling 6,050 shares during the quarter. BNP Paribas Financial Markets' holdings in Glaukos were worth $1,151,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in GKOS. Barclays PLC boosted its stake in shares of Glaukos by 394.4% during the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock valued at $11,686,000 after buying an additional 71,556 shares during the last quarter. LVW Advisors LLC boosted its stake in shares of Glaukos by 22.2% during the 4th quarter. LVW Advisors LLC now owns 2,273 shares of the medical instruments supplier's stock valued at $341,000 after buying an additional 413 shares during the last quarter. Zhang Financial LLC bought a new position in Glaukos during the fourth quarter worth $221,000. SG Americas Securities LLC lifted its stake in Glaukos by 42.1% during the fourth quarter. SG Americas Securities LLC now owns 3,641 shares of the medical instruments supplier's stock worth $546,000 after purchasing an additional 1,078 shares during the last quarter. Finally, Avior Wealth Management LLC bought a new position in Glaukos during the fourth quarter worth $390,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.80% of the stock is owned by company insiders.

Glaukos Stock Performance

Shares of GKOS traded down $0.97 during trading hours on Monday, reaching $96.22. 829,075 shares of the company's stock traded hands, compared to its average volume of 698,019. The business's fifty day simple moving average is $93.33 and its two-hundred day simple moving average is $124.22. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of -33.53 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. During the same quarter last year, the business posted ($0.70) EPS. Glaukos's revenue was up 24.6% on a year-over-year basis. Analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on GKOS shares. Truist Financial restated a "buy" rating and set a $135.00 price objective (down from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Morgan Stanley reduced their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Piper Sandler reduced their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 15th. Stifel Nicolaus reduced their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $160.00 to $86.00 in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $134.67.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.